Technology insight:: Calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease

被引:56
|
作者
Lundberg, J [1 ]
Hellström, PM
Fagerhol, MK
Weitzberg, E
Roseth, AG
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden
[2] Ullevaal Univ Hosp, Oslo, Norway
[3] Aker Univ Hosp, Oslo, Norway
来源
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2005年 / 2卷 / 02期
关键词
calprotectin; fecal marker; inflammatory bowel disease; lactoferrin; nitric oxide;
D O I
10.1038/ncpgasthep0094
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Distinguishing patients with inflammatory bowel disease from those with irritable bowel syndrome can be difficult. A simple and reliable test that detects intestinal inflammation would therefore be very useful in the clinic. If such a test parameter correlated with the intensity of the inflammatory reaction it could also be used to monitor disease activity. Calprotectin, lactoferrin and nitric oxide are produced and released locally in much greater quantities in the inflamed gut than in the noninflamed gut. These compounds can be readily measured in fecal samples (calprotectin and lactoferrin) or directly in the intestinal lumen (nitric oxide gas). Here, we discuss what is known about these markers, how they could be used in clinical practice and how they can complement existing techniques used for the diagnosis and monitoring of inflammatory bowel disease.
引用
收藏
页码:96 / 102
页数:7
相关论文
共 50 条
  • [41] Salivary calprotectin and neutrophils in inflammatory bowel disease in relation to oral diseases
    Majster, Mirjam
    Almer, Sven
    Malmqvist, Sebastian
    Johannsen, Annsofi
    Lira-Junior, Ronaldo
    Bostroem, Elisabeth Almer
    ORAL DISEASES, 2025, 31 (01) : 286 - 297
  • [42] Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease
    Konikoff, Michael R.
    Denson, Lee A.
    INFLAMMATORY BOWEL DISEASES, 2006, 12 (06) : 524 - 534
  • [43] Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
    D'Haens, Geert
    Ferrante, Marc
    Vermeire, Severine
    Baert, Filip
    Noman, Maja
    Moortgat, Liesbeth
    Geens, Patricia
    Iwens, Doreen
    Aerden, Isolde
    Van Assche, Gert
    Van Olmen, Gust
    Rutgeerts, Paul
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (12) : 2218 - 2224
  • [44] Interventions of natural and synthetic agents in inflammatory bowel disease, modulation of nitric oxide pathways
    Aida Kamalian
    Masoud Sohrabi Asl
    Mahsa Dolatshahi
    Khashayar Afshari
    Shiva Shamshiri
    Nazanin Momeni Roudsari
    Saeideh Momtaz
    Roja Rahimi
    Mohammad Abdollahi
    Amir Hossein Abdolghaffari
    World Journal of Gastroenterology, 2020, 26 (24) : 3365 - 3400
  • [45] Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: Correlation with laboratory parameters, clinical, endoscopic and histological indexes
    Vieira A.
    Fang C.B.
    Rolim E.G.
    Klug W.A.
    Steinwurz F.
    Rossini L.G.B.
    Candelria P.A.
    BMC Research Notes, 2 (1)
  • [46] The Role of Calprotectin in the Diagnosis and Treatment of Inflammatory Bowel Disease
    Wang, Wenqian
    Cao, Wenfu
    Zhang, Shenyun
    Chen, Dapeng
    Liu, Lihong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [47] Elevated levels of alveolar nitric oxide in patients with inflammatory bowel disease
    Protopapas, Adonis
    Vradelis, Stergios
    Karampitsakos, Theodoros
    Chatzimichail, Athanasios
    Paraskakis, Emmanouil
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [48] Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle
    Kolios, G
    Valatas, V
    Ward, SG
    IMMUNOLOGY, 2004, 113 (04) : 427 - 437
  • [49] Fecal lactoferrin, a marker of intestinal inflammation in children with inflammatory bowel disease
    Borkowska, Anna
    Liberek, Anna
    Luczak, Grazyna
    Jankowska, Agnieszka
    Plata-Nazar, Katarzyna
    Korzon, Maria
    Kaminska, Barbara
    ACTA BIOCHIMICA POLONICA, 2015, 62 (03) : 541 - 545
  • [50] Salivary Calprotectin is Not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease
    Bos, Vincent
    Crouwel, Femke
    Waaijenberg, Petra
    Bouma, Gerd
    Duijvestein, Marjolijn
    Buiter, Hans J. C.
    Brand, Henk S.
    Hamer, Henrike M.
    De Boer, Nanne K.
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2022, 31 (03) : 283 - 289